Truist initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $99 price target The firm says the company has “gone big” in targeting one of the biggest drivers of cancer where mutations drive one-third of all new cancer diagnoses. Revolution has built the broadest pipeline attacking RAS-mutant cancer targets, including a “coveted” multi-target pan inhibitor in daraxonrasib, which could be an $8B-plus drug, the analyst tells investors in a research note. Truist believes the current share price misses the “revolutionary potential” of Revolution’s drugs when used in combinations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Piper starts Revolution Medicines at Overweight on daraxonrasib potential
- Revolution Medicines initiated with an Overweight at Piper Sandler
- Revolution Medicines initiated with an Outperform at LifeSci Capital
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Overweight at Wells Fargo